Samsung Biologics (KRX: 207940)
Who is buying Samsung Biologics?
Between Sep 10, 2026 and Oct 13, 2026 (20 trading sessions), foreign investors net sold ₩115.9bn ($87M) of Samsung Biologics, the 24th largest foreign net sale among 832 KOSPI stocks. Institutions net sold ₩89.3bn ($67M) and retail investors net bought ₩195.3bn ($147M) over the same window. Foreigners were net buyers on 10 of the 20 sessions.
Foreign investors hold 12.92% of Samsung Biologics' listed shares (KRX ownership data as of Oct 13, 2026), down from 13.13% twenty sessions earlier and 12.83% a year ago.
The stock closed at ₩1,206,000 on Oct 13, 2026: -16.30% over 20 sessions, -28.30% year-to-date, -19.04% over one year.
At ₩1,206,000 the stock trades at 25.79× 12-month-forward consensus earnings (19 analysts), 24.95× on FY2027 estimates. The trailing P/E published by KRX is 45.64×, based on the last completed fiscal year.
View chart data as a table
| Date | Close | Foreign net | Institutions | Retail |
|---|---|---|---|---|
| 2026-10-13 | ₩1,206,000 | ₩-2.8bn | +₩10.5bn | ₩-7.4bn |
| 2026-10-12 | ₩1,201,000 | ₩-15.3bn | +₩5.8bn | +₩9.1bn |
| 2026-10-08 | ₩1,219,000 | ₩-24.2bn | ₩-11.5bn | +₩35.4bn |
| 2026-10-07 | ₩1,277,000 | ₩-27.9bn | ₩-11.4bn | +₩37.9bn |
| 2026-10-06 | ₩1,310,000 | ₩-62.5bn | +₩0.9bn | +₩58.3bn |
| 2026-10-02 | ₩1,354,000 | ₩-47.0bn | ₩-4.2bn | +₩50.1bn |
| 2026-10-01 | ₩1,418,000 | +₩18.8bn | +₩3.0bn | ₩-21.6bn |
| 2026-09-30 | ₩1,380,293 | +₩6.6bn | ₩-0.3bn | ₩-6.4bn |
| 2026-09-29 | ₩1,374,339 | ₩-5.9bn | ₩-1.4bn | +₩7.3bn |
| 2026-09-28 | ₩1,389,223 | +₩13.1bn | +₩2.1bn | ₩-14.8bn |
| 2026-09-23 | ₩1,355,485 | ₩-11.0bn | ₩-9.2bn | +₩19.4bn |
| 2026-09-22 | ₩1,380,293 | +₩1.7bn | ₩-13.2bn | +₩10.4bn |
| 2026-09-21 | ₩1,391,208 | +₩4.8bn | ₩-5.4bn | +₩0.1bn |
| 2026-09-18 | ₩1,387,239 | ₩-0.7bn | ₩-1.5bn | +₩1.9bn |
| 2026-09-17 | ₩1,385,254 | +₩1.7bn | ₩-8.5bn | +₩6.9bn |
| 2026-09-16 | ₩1,398,154 | ₩-7.0bn | +₩2.5bn | +₩3.6bn |
| 2026-09-15 | ₩1,401,131 | +₩0.8bn | +₩0.0bn | ₩-0.8bn |
| 2026-09-14 | ₩1,409,069 | +₩5.8bn | ₩-1.8bn | ₩-4.0bn |
| 2026-09-11 | ₩1,404,108 | +₩4.7bn | ₩-5.3bn | +₩0.2bn |
| 2026-09-10 | ₩1,412,046 | +₩30.3bn | ₩-40.5bn | +₩9.7bn |
| 2026-09-09 | ₩1,440,823 | +₩7.8bn | ₩-8.3bn | +₩0.4bn |
| 2026-09-08 | ₩1,428,915 | +₩2.5bn | ₩-14.3bn | +₩11.8bn |
| 2026-09-07 | ₩1,454,715 | +₩11.2bn | ₩-5.9bn | ₩-4.7bn |
| 2026-09-04 | ₩1,435,861 | ₩-4.3bn | ₩-7.5bn | +₩11.7bn |
| 2026-09-03 | ₩1,465,631 | ₩-1.9bn | ₩-5.8bn | +₩6.4bn |
| 2026-09-02 | ₩1,489,446 | +₩6.2bn | ₩-7.0bn | +₩0.5bn |
| 2026-09-01 | ₩1,508,300 | +₩10.1bn | ₩-3.4bn | ₩-6.6bn |
| 2026-08-31 | ₩1,506,315 | +₩9.2bn | ₩-1.8bn | ₩-9.4bn |
| 2026-08-28 | ₩1,474,561 | ₩-28.8bn | ₩-12.8bn | +₩41.3bn |
| 2026-08-27 | ₩1,581,730 | +₩4.7bn | +₩0.8bn | ₩-5.2bn |
| 2026-08-26 | ₩1,586,691 | +₩7.7bn | +₩6.9bn | ₩-13.6bn |
| 2026-08-25 | ₩1,572,799 | ₩-4.3bn | +₩21.8bn | ₩-17.6bn |
| 2026-08-24 | ₩1,560,892 | +₩7.1bn | +₩7.3bn | ₩-13.2bn |
| 2026-08-21 | ₩1,539,061 | +₩6.4bn | ₩-0.0bn | ₩-6.3bn |
| 2026-08-20 | ₩1,561,884 | +₩13.2bn | ₩-5.8bn | ₩-5.4bn |
| 2026-08-19 | ₩1,532,115 | +₩5.9bn | ₩-0.4bn | ₩-5.8bn |
| 2026-08-18 | ₩1,519,215 | +₩1.2bn | ₩-1.6bn | +₩0.7bn |
| 2026-08-14 | ₩1,536,084 | ₩-1.9bn | ₩-10.8bn | +₩13.0bn |
| 2026-08-13 | ₩1,551,961 | +₩38.3bn | ₩-39.4bn | +₩2.4bn |
| 2026-08-12 | ₩1,537,076 | +₩8.8bn | ₩-22.8bn | +₩15.0bn |
| 2026-08-11 | ₩1,596,614 | +₩25.6bn | +₩26.7bn | ₩-49.6bn |
| 2026-08-10 | ₩1,556,922 | +₩15.9bn | +₩1.0bn | ₩-17.8bn |
| 2026-08-07 | ₩1,544,022 | +₩20.2bn | +₩20.1bn | ₩-36.7bn |
| 2026-08-06 | ₩1,502,346 | +₩18.1bn | +₩1.4bn | ₩-18.6bn |
| 2026-08-05 | ₩1,479,523 | +₩25.6bn | ₩-13.8bn | ₩-11.6bn |
| 2026-08-04 | ₩1,464,638 | +₩28.6bn | ₩-12.3bn | ₩-15.5bn |
| 2026-08-03 | ₩1,412,046 | ₩-0.0bn | ₩-21.8bn | +₩20.8bn |
| 2026-07-31 | ₩1,473,569 | ₩-7.1bn | ₩-31.3bn | +₩35.4bn |
| 2026-07-30 | ₩1,515,246 | +₩2.2bn | +₩28.4bn | ₩-26.2bn |
| 2026-07-29 | ₩1,467,615 | ₩-12.1bn | +₩33.6bn | ₩-20.8bn |
| 2026-07-28 | ₩1,537,076 | ₩-24.8bn | +₩82.5bn | ₩-50.6bn |
| 2026-07-27 | ₩1,533,107 | ₩-7.9bn | +₩47.5bn | ₩-40.6bn |
| 2026-07-24 | ₩1,506,315 | +₩115.1bn | +₩112.0bn | ₩-220.8bn |
| 2026-07-23 | ₩1,368,385 | ₩-8.2bn | ₩-2.5bn | +₩10.4bn |
| 2026-07-22 | ₩1,361,439 | +₩2.7bn | ₩-1.6bn | ₩-1.4bn |
| 2026-07-21 | ₩1,384,262 | ₩-0.2bn | +₩16.1bn | ₩-15.6bn |
| 2026-07-20 | ₩1,334,647 | ₩-18.8bn | +₩6.2bn | +₩8.0bn |
| 2026-07-16 | ₩1,385,254 | +₩3.8bn | +₩3.2bn | ₩-6.7bn |
| 2026-07-15 | ₩1,372,354 | +₩24.0bn | ₩-14.1bn | ₩-9.1bn |
| 2026-07-14 | ₩1,357,470 | ₩-6.1bn | +₩2.2bn | +₩3.9bn |
| 2026-07-13 | ₩1,389,223 | +₩5.0bn | +₩17.8bn | ₩-22.3bn |
Investor flows summary
| Window | Foreign | (USD) | Institutions | Retail |
|---|---|---|---|---|
| 1 day | ₩-2.8bn | $-2M | +₩10.5bn | ₩-7.4bn |
| 5 days | ₩-132.7bn | $-100M | ₩-5.7bn | +₩133.4bn |
| 20 days | ₩-115.9bn | $-87M | ₩-89.3bn | +₩195.3bn |
Positive = net buying, negative = net selling. Values aggregate the KRX main board and the NXT alternative venue.
Frequently asked questions
Are foreign investors buying Samsung Biologics stock?
Over the last 5 sessions foreign investors net sold ₩132.7bn ($100M) of Samsung Biologics; over 60 sessions they net bought ₩179.7bn ($135M); since Jan 1, 2026 they net bought ₩242.8bn ($182M). Over 20 sessions the stock is the 24th largest foreign net sale among 832 KOSPI stocks.
How much of Samsung Biologics do foreign investors own?
Foreign investors own 12.92% of Samsung Biologics' shares as of Oct 13, 2026, versus 12.83% one year earlier. The figure is KRX's daily foreign holdings divided by listed shares, and it reflects trades settled through the previous session.
Who is on the other side — institutions or retail investors?
Over 20 sessions institutions net sold ₩89.3bn ($67M) and retail investors net bought ₩195.3bn ($147M) of Samsung Biologics. Retail investors have been absorbing what foreigners and institutions are selling.
Is Samsung Biologics listed on KOSPI or KOSDAQ?
Samsung Biologics (삼성바이오로직스) trades on KOSPI under KRX code 207940 in the Biotech & Pharma group, with a market capitalization of ₩56T ($41.9B). Daily net flows by investor type are published by KRX after each session and combine the KRX main board with the NXT venue.
Annual financials
| Fiscal year | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| 2023 | ₩3.7T ($2.8B) | – | ₩1.1T ($835M) | ₩858bn ($643M) |
| 2024 | ₩4.5T ($3.4B) | +23.10% | ₩1.3T ($990M) | ₩1.1T ($813M) |
| 2025 | ₩4.6T ($3.4B) | +0.20% | ₩2.1T ($1.6B) | ₩1.8T ($1.3B) |
Consolidated (K-IFRS) where available, from DART regulatory filings. USD figures converted at the current rate (₩1333.09/$) for reference only.